RENB Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 May 2024 @ 11:32):

Stats
Today's Volume	74 663.00
Average Volume	355 398
Market Cap	206.88M
EPS	$0 ( 2024-02-13 )
Next earnings date	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.06
ATR14	$0.0140 (0.97%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-06	Sapirstein James	Buy	28 196	Option to Purchase Common Stock
2024-03-11	Tarsh Simon	Buy	10 000	Option to purchase shares of common stock
2024-03-11	Tarsh Simon	Buy	0
2023-12-27	Brosgart Carol L	Buy	23 810	Option to purchase shares of common stock
2022-02-13	Brink Karen	Buy	0	Common Stock

INSIDER POWER
49.92
Last 81 transactions
Buy: 42 181 029 \| Sell: 31 304 389

Volume Correlation

Long: 0.20 (neutral)

Short: 0.89 (strong)

Signal:(37.013) Same movement expected

Renovaro Biosciences Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Renovaro Biosciences Inc. Correlation - Currency/Commodity

-0.50
( neutral )

-0.57
( weak negative )

0.00
( neutral )

-0.42
( neutral )

-0.71
( moderate negative )

0.61
( weak )

Financial Reports:

No articles found.

Renovaro Biosciences Inc.

Renovaro Biosciences Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Enochian Biosciences, Inc. and changed its name to Renovaro Biosciences Inc. in August 2023. Renovaro Biosciences Inc. is headquartered in Los Angeles, California.